TGF-β and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease

Bone Research

Volumn 4, Issue , 2016, Pages

  Wu, Mengrui ^a   Chen, Guiqian ^a,b   Li, Yi Ping ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; FIBROBLAST GROWTH FACTOR; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE P38; NOGGIN; NOTCH RECEPTOR; PROTEASOME; SMAD PROTEIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN; WNT PROTEIN;

ARTICLE; BONE DEVELOPMENT; BONE DISEASE; BRACHYDACTYLY; CARTILAGE CELL; CELL DIFFERENTIATION; DEVELOPMENTAL DISORDER; DISEASE SEVERITY; EPIGENETICS; EXTRACELLULAR MATRIX; FIBROUS DYSPLASIA; GENE; GENE MUTATION; GENETIC REGULATION; HOMEOSTASIS; HUMAN; MESENCHYMAL STEM CELL; MESENCHYME CELL; MOUSE; MYHRE SYNDROME; NONHUMAN; OSSIFICATION; OSTEOBLAST; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY;

EID: 84979021935     PISSN: 20954700     EISSN: 20956231     Source Type: Journal    
DOI: 10.1038/boneres.2016.9     Document Type: Article

References (258)

1. Guo X, Wang XF. Signaling cross-talk between TGF /BMP and other pathways. Cell Res 2009; 19: 71-88.
2. Feng XH, Derynck R. Specificity and versatility in tgf-beta signaling through Smads. Annu Rev Cell Dev Biol 2005; 21: 659-693.
3. Bernabeu C, Lopez-Novoa JM, Quintanilla M. The emerging role of TGF-beta superfamily coreceptors in cancer. Biochim Biophys Acta 2009; 1792: 954-973.
4. Chen G, Deng C, Li YP. TGF and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci 2012; 8: 272-288.
5. Berendsen AD, Olsen BR. Bone development. Bone 2015; 80: 14-18.
6. Long F, Ornitz DM. Development of the endochondral skeleton. Cold Spring Harb Perspect Biol 2013; 5: a008334.
7. Crane JL, Xian L, Cao X. Role of TGF signaling in coupling bone remodeling. Methods Mol Biol 2016; 1344: 287-300.
8. Tang Y, Wu X, Lei W et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med 2009; 15: 757-765.
9. Li YP, Chen W, Stashenko P. Molecular cloning and characterization of a putative novel human osteoclast-specific 116-kDa vacuolar proton pump subunit. Biochem Biophys Res Commun 1996; 218: 813-821.
10. Li YP, Chen W, Liang Y et al. Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification. Nat Genet 1999; 23: 447-451.
11. Chen W, Yang S, Abe Y et al. Novel pycnodysostosis mouse model uncovers cathepsin K function as a potential regulator of osteoclast apoptosis and senescence. Hum Mol Genet 2007; 16: 410-423.
12. Li YP, Alexander M, Wucherpfenni AL et al. Cloning and complete coding sequence of a novel human cathepsin expressed in giant cells of osteoclastomas. J Bone Miner Res 1995; 8: 1197-1202.
13. Razzouk S, Sarkis R. BMP-2: biological challenges to its clinical use. N Y State Dent J 2012; 78: 37-39.
14. Kanakaris NK, Giannoudis PV. Clinical applications of bone morphogenetic proteins: current evidence. J Surg Orthop Adv 2008; 17: 133-146.
15. Zhang W, Zhou M, Liu C et al. A novel mutation of SMAD3 identified in a Chinese family with aneurysms-osteoarthritis syndrome. BioMed Res Int 2015; 2015: 1-6.
16. Dodd AW, Syddall CM, Loughlin J. A rare variant in the osteoarthritisassociated locus GDF5 is functional and reveals a site that can be manipulated to modulate GDF5 expression. Eur J Hum Genet 2013; 21: 517-521.
17. van der Kraan PM, Goumans MJ, Blaney Davidson E et al. Agedependent alteration of TGF signalling in osteoarthritis. Cell Tissue Res 2012; 347: 257-265.
18. Hayashi M, Muneta T, Ju YJ et al. Weekly intra-articular injections of bone morphogenetic protein-7 inhibits osteoarthritis progression. Arthritis Res Ther 2008; 10: R118.
19. Blaney Davidson EN, van der Kraan PM, van den Berg WB. TGF-beta and osteoarthritis. Osteoarthritis Cartilage 2007; 15: 597-604.
20. van den Bosch MH, Blom AB, van Lent PL et al. Canonical Wnt signaling skews TGF signaling in chondrocytes towards signaling via ALK1 and Smad 1/5/8. Cell Signal 2014; 26: 951-958.
21. Sakou T, Onishi T, Yamamoto T et al. Localization of Smads, the TGF family intracellular signaling components during endochondral ossification. J Bone Miner Res 1999; 14: 1145-1152.
22. Serra R, Karaplis A, Sohn P. Parathyroid hormone-related peptide (PTHrP)-dependent and-independent effects of transforming growth factor beta (TGF-beta) on endochondral bone formation. J Cell Biol 1999; 145: 783-794.
23. Li TF, O'Keefe RJ, Chen D. TGF-beta signaling in chondrocytes. Front Biosci 2005; 10: 681-688.
24. Sanford LP, Ormsby I, Gittenberger-de Groot AC et al. TGF beta2 knockout mice have multiple developmental defects that are nonoverlapping with other TGFbeta knockout phenotypes. Development 1997; 124: 2659-2670.
25. Kulkarni AB, Huh CG, Becker D et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 1993; 90: 770-774.
26. Kaartinen V, Voncken JW, Shuler C et al. Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction. Nat Genet 1995; 11: 415-421.
27. Proetzel G, Pawlowski SA, Wiles MV et al. Transforming growth factor-beta 3 is required for secondary palate fusion. Nat Genet 1995; 11: 409-414.
28. Crane JL, Cao X. Bone marrow mesenchymal stem cells and TGF signaling in bone remodeling. J Clin Invest 2014; 124: 466-472.
29. Karsdal MA, Larsen L, Engsig MT et al. Matrix metalloproteinasedependent activation of latent transforming growth factor-beta controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis. J Biol Chem 2002; 277: 44061-44067.
30. Matsunobu T, Torigoe K, Ishikawa M et al. Critical roles of the TGFbeta type I receptor ALK5 in perichondrial formation and function, cartilage integrity, and osteoblast differentiation during growth plate development. Dev Biol 2009; 332: 325-338.
31. Karst M, Gorny G, Galvin RJ et al. Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-beta regulation of osteoclast differentiation. J Cell Physiol 2004; 200: 99-106.
32. Yasui T, Kadono Y, Nakamura M et al. Regulation of RANKL-induced osteoclastogenesis by TGF through molecular interaction between Smad3 and Traf6. J Bone Miner Res 2011; 26: 1447-1456.
33. Leah E. Osteoarthritis: TGF overload at bones of cartilage degeneration. Nat Rev Rheumatol 2013; 9: 382.
34. Serra R, Johnson M, Filvaroff EH et al. Expression of a truncated, kinase-defective TGF-beta type II receptor in mouse skeletal tissue promotes terminal chondrocyte differentiation and osteoarthritis. J Cell Biol 1997; 139: 541-552.
35. Bush JR, Beier F. TGF and osteoarthritis-the good and the bad. Nat Med 2013; 19: 667-669.
36. van der Kraan PM. Age-related alterations in TGF beta signaling as a causal factor of cartilage degeneration in osteoarthritis. Biomed Mater Eng 2014; 24 1 Suppl: 75-80.
37. Zhen G, Wen C, Jia X et al. Inhibition of TGF signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. Nat Med 2013; 19: 704-712.
38. Xu X, Zheng L, Bian Q et al. Aberrant activation of TGF in subchondral bone at the onset of rheumatoid arthritis joint destruction. J Bone Miner Res 2015; 30: 2033-2043.
39. Dabovic B, Levasseur R, Zambuto L et al. Osteopetrosis-like phenotype in latent TGF-beta binding protein 3 deficient mice. Bone 2005; 37: 25-31.
40. Koli K, Ryynänen MJ, Keski-Oja J. Latent TGF-beta binding proteins (LTBPs)-1 and-3 coordinate proliferation and osteogenic differentiation of human mesenchymal stem cells. Bone 2008; 43: 679-688.
41. Nikitovic D, Aggelidakis J, Young MF et al. The biology of small leucine-rich proteoglycans in bone pathophysiology. J Biol Chem 2012; 287: 33926-33933.
42. Grafe I, Yang T, Alexander S et al. Excessive transforming growth factor signaling is a common mechanism in osteogenesis imperfecta. Nat Med 2014; 20: 670-675.
43. Qiu T, Wu X, Zhang F et al. TGF-beta type II receptor phosphorylates PTH receptor to integrate bone remodelling signalling. Nat Cell Biol 2010; 12: 224-234.
44. Longobardi L, Li T, Myers TJ et al. TGF type II receptor/MCP-5 axis: at the crossroad between joint and growth plate development. Dev Cell 2012; 23: 71-81.
45. Spagnoli A, O'Rear L, Chandler RL et al. TGF-beta signaling is essential for joint morphogenesis. J Cell Biol 2007; 177: 1105-1117.
46. Seo HS, Serra R. Deletion of Tgfbr2 in Prx1-cre expressing mesenchyme results in defects in development of the long bones and joints. Dev Biol 2007; 310: 304-316.
47. Baffi MO, Slattery E, Sohn P et al. Conditional deletion of the TGF-beta type II receptor in Col2a expressing cells results in defects in the axial skeleton without alterations in chondrocyte differentiation or embryonic development of long bones. Dev Biol 2004; 276: 124-142.
48. Kang JS, Alliston T, Delston R et al. Repression of Runx2 function by TGF-beta through recruitment of class II histone deacetylases by Smad3. EMBO J 2005; 24: 2543-2555.
49. Alliston T, Choy L, Ducy P et al. TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. EMBO J 2001; 20: 2254-2272.
50. Hjelmeland AB, Schilling SH, Guo X et al. Loss of Smad3-mediated negative regulation of Runx2 activity leads to an alteration in cell fate determination. Mol Cell Biol 2005; 25: 9460-9468.
51. Li J, Tsuji K, Komori T et al. Smad2 overexpression enhances Smad4 gene expression and suppresses CBFA1 gene expression in osteoblastic osteosarcoma ROS17/2. 8 cells and primary rat calvaria cells. J Biol Chem 1998; 273: 31009-31015.
52. Borton AJ, Frederick JP, DattoMB et al. The loss of Smad3 results in a lower rate of bone formation and osteopenia through dysregulation of osteoblast differentiation and apoptosis. J Bone Miner Res 2001; 16: 1754-1764.
53. Kaji H, Naito J, Sowa H et al. Smad3 differently affects osteoblast differentiation depending upon its differentiation stage. Horm Metab Res 2006; 38: 740-745.
54. Ferguson CM, Schwarz EM, Reynolds PR et al. Smad2 and 3 mediate transforming growth factor-beta1-induced inhibition of chondrocyte maturation. Endocrinology 2000; 141: 4728-4735.
55. Alvarez J, Serra R. Unique and redundant roles of Smad3 in TGF-betamediated regulation of long bone development in organ culture. Dev Dyn 2004; 230: 685-699.
56. Li TF, Darowish M, Zuscik MJ et al. Smad3-deficient chondrocytes have enhanced BMP signaling and accelerated differentiation. J Bone Miner Res 2006; 21: 4-16.
57. Ashcroft GS, Yang X, Glick AB et al. Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat Cell Biol 1999; 1: 260-266.
58. Chen CG, Thuillier D, Chin EN et al. Chondrocyte-intrinsic Smad3 represses Runx2-inducible matrix metalloproteinase 13 expression to maintain articular cartilage and prevent osteoarthritis. Arthritis Rheum 2012; 64: 3278-3289.
59. Yang X, Chen L, Xu X et al. TGF-beta/Smad3 signals repress chondrocyte hypertrophic differentiation and are required for maintaining articular cartilage. J Cell Biol 2001; 153: 35-46.
60. van de Laar IM, Oldenburg RA, Pals G et al. Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat Genet 2011; 43: 121-126.
61. van de Laar IM, van der Linde D, Oei EH et al. Phenotypic spectrum of the SMAD3-related aneurysms-osteoarthritis syndrome. J Med Genet 2012; 49: 47-57.
62. Lee KS, Hong SH, Bae SC. Both the Smad and p38 MAPK pathways play a crucial role in Runx2 expression following induction by transforming growth factor and bone morphogenetic protein. Oncogene 2002; 21: 7156-7163.
63. Lai CF, Cheng SL. Signal transductions induced by bone morphogenetic protein-2 and transforming growth factor-beta in normal human osteoblastic cells. J Biol Chem 2002; 277: 15514-15522.
64. Luu HH, Song WX, Luo X et al. Distinct roles of bone morphogenetic proteins in osteogenic differentiation of mesenchymal stem cells. J Orthop Res 2007; 25: 665-677.
65. Abula K, Muneta T, Miyatake K et al. Elimination of BMP7 from the developing limb mesenchyme leads to articular cartilage degeneration and synovial inflammation with increased age. FEBS Lett 2015; 589: 1240-1248.
66. Huang Z, Ren PG, Ma T et al. Modulating osteogenesis of mesenchymal stem cells by modifying growth factor availability. Cytokine 2010; 51: 305-310.
67. Noël D, Gazit D, Bouquet C et al. Short-term BMP-2 expression is sufficient for in vivo osteochondral differentiation of mesenchymal stem cells. Stem Cells 2004; 22: 74-85.
68. Gu K, Zhang L, Jin T et al. Identification of potential modifiers of Runx2/Cbfa1 activity in C2C12 cells in response to bone morphogenetic protein-7. Cells Tissues Organs (Print) 2004; 176: 28-40.
69. Shen B, Wei A, Whittaker S et al. The role of BMP-7 in chondrogenic and osteogenic differentiation of human bone marrow multipotent mesenchymal stromal cells in vitro. J Cell Biochem 2010; 109: 406-416.
70. Tsuji K, Cox K, Gamer L et al. Conditional deletion of BMP7 from the limb skeleton does not affect bone formation or fracture repair. J Orthop Res 2010; 28: 384-389.
71. Kokabu S, Gamer L, Cox K et al. BMP3 suppresses osteoblast differentiation of bone marrow stromal cells via interaction with Acvr2b. Mol Endocrinol 2012; 26: 87-94.
72. Daluiski A, Engstrand T, Bahamonde ME et al. Bone morphogenetic protein-3 is a negative regulator of bone density. Nat Genet 2001; 27: 84-88.
73. Gamer LW, Cox K, Carlo JM et al. Overexpression of BMP3 in the developing skeleton alters endochondral bone formation resulting in spontaneous rib fractures. Dev Dyn 2009; 238: 2374-2381.
74. Chan CK, Seo EY, Chen JY et al. Identification and specification of the mouse skeletal stem cell. Cell 2015; 160: 285-298.
75. Worthley DL, Churchill M, Compton JT et al. Gremlin 1 identifies a skeletal stem cell with bone, cartilage, and reticular stromal potential. Cell 2015; 160: 269-284.
76. Minina E, Kreschel C, Naski MC et al. Interaction of FGF, IHH/Pthlh, and BMP signaling integrates chondrocyte proliferation and hypertrophic differentiation. Dev Cell 2002; 3: 439-449.
77. Kobayashi T, Lyons KM, McMahon AP et al. BMP signaling stimulates cellular differentiation at multiple steps during cartilage development. Proc Natl Acad Sci USA 2005; 102: 18023-18027.
78. Komatsu Y, Kaartinen V, Mishina Y. Cell cycle arrest in node cells governs ciliogenesis at the node to break left-right symmetry. Development 2011; 138: 3915-3920.
79. Haas AR, Tuan RS. Chondrogenic differentiation of murine C3H10T1/2 multipotential mesenchymal cells: II. Stimulation by bone morphogenetic protein-2 requires modulation of N-cadherin expression and function. Differentiation 1999; 64: 77-89.
80. Luo G, Hofmann C, Bronckers AL et al. BMP-7 is an inducer of nephrogenesis, and is also required for eye development and skeletal patterning. Genes Dev 1995; 9: 2808-2820.
81. Selever J, Liu W, Lu MF et al. Bmp4 in limb bud mesoderm regulates digit pattern by controlling AER development. Dev Biol 2004; 276: 268-279.
82. Bandyopadhyay A, Tsuji K, Cox K et al. Genetic analysis of the roles of BMP2, BMP4, and BMP7 in limb patterning and skeletogenesis. PLoS Genet 2006; 2: e216.
83. Tsuji K, Bandyopadhyay A, Harfe BD et al. BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. Nat Genet 2006; 38: 1424-1429.
84. Tsuji K, Cox K, Bandyopadhyay A et al. BMP4 is dispensable for skeletogenesis and fracture-healing in the limb. J Bone Joint Surg Am 2008; 90 Suppl 1: 14-18.
85. Long F. Building strong bones: molecular regulation of the osteoblast lineage. Nat Rev Mol Cell Biol 2012; 13: 27-38.
86. Shu B, Zhang M, Xie R et al. BMP2, but not BMP4, is crucial for chondrocyte proliferation and maturation during endochondral bone development. J Cell Sci 2011; 124 Pt 20: 3428-3440.
87. Sekiya I, Tang T, Hayashi M et al. Periodic knee injections of BMP-7 delay cartilage degeneration induced by excessive running in rats. J Orthop Res 2009; 27: 1088-1092.
88. Takahashi T, Muneta T, Tsuji K et al. BMP-7 inhibits cartilage degeneration through suppression of inflammation in rat zymosan-induced arthritis. Cell Tissue Res 2011; 344: 321-332.
89. Rountree RB, Schoor M, Chen H et al. BMP receptor signaling is required for postnatal maintenance of articular cartilage. PLoS Biol 2004; 2: e355.
90. Medici D, Shore EM, Lounev VY et al. Conversion of vascular endothelial cells into multipotent stem-like cells. Nat Med 2010; 16: 1400-1406.
91. Shore EM, Xu M, Feldman GJ et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet 2006; 38: 525-527.
92. Shen Q, Little SC, Xu M et al. The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization. J Clin Invest 2009; 119: 3462-3472.
93. van Dinther M, Visser N, de Gorter DJ et al. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation. J Bone Miner Res 2010; 25: 1208-1215.
94. Yang C, Yang L, Wan M et al. Generation of a mouse model with expression of bone morphogenetic protein type II receptor lacking the cytoplasmic domain in osteoblasts. Ann N Y Acad Sci 2010; 1192: 286-291.
95. Mishina Y, Starbuck MW, Gentile MA et al. Bone morphogenetic protein type IA receptor signaling regulates postnatal osteoblast function and bone remodeling. J Biol Chem 2004; 279: 27560-27566.
96. Kamiya N, Kobayashi T, Mochida Y et al. Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts. J Bone Miner Res 2010; 25: 200-210.
97. Kamiya N, Ye L, Kobayashi T et al. Disruption of BMP signaling in osteoblasts through type IA receptor (BMPRIA) increases bone mass. J Bone Miner Res 2008; 23: 2007-2017.
98. Kamiya N, Ye L, Kobayashi T et al. BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway. Development 2008; 135: 3801-3811.
99. Dewulf N, Verschueren K, Lonnoy O et al. Distinct spatial and temporal expression patterns of two type I receptors for bone morphogenetic proteins during mouse embryogenesis. Endocrinology 1995; 136: 2652-2663.
100. Francis PH, Richardson MK, Brickell PM et al. Bone morphogenetic proteins and a signalling pathway that controls patterning in the developing chick limb. Development 1994; 120: 209-218.
101. Kawakami Y, Ishikawa T, Shimabara M et al. BMP signaling during bone pattern determination in the developing limb. Development 1996; 122: 3557-3566.
102. Yamaji N, Celeste AJ, Thies RS et al. A mammalian serine/threonine kinase receptor specifically binds BMP-2 and BMP-4. Biochem Biophys Res Commun 1994; 205: 1944-1951.
103. Zou H, Wieser R, Massagué J et al. Distinct roles of type I bone morphogenetic protein receptors in the formation and differentiation of cartilage. Genes Dev 1997; 11: 2191-2203.
104. Yoon BS, Ovchinnikov DA, Yoshii I et al. Bmpr1a and Bmpr1b have overlapping functions and are essential for chondrogenesis in vivo. Proc Natl Acad Sci USA 2005; 102: 5062-5067.
105. Rigueur D, Brugger S, Anbarchian T et al. The type I BMP receptor ACVR1/ALK2 is required for chondrogenesis during development. J Bone Miner Res 2015; 30: 733-741.
106. Enomoto-Iwamoto M, Iwamoto M, Mukudai Y et al. Bone morphogenetic protein signaling is required for maintenance of differentiated phenotype, control of proliferation, and hypertrophy in chondrocytes. J Cell Biol 1998; 140: 409-418.
107. Fujii M, Takeda K, Imamura T et al. Roles of bone morphogenetic protein type I receptors and Smad proteins in osteoblast and chondroblast differentiation. Mol Biol Cell 1999; 10: 3801-3813.
108. Zhang D, Schwarz EM, Rosier RN et al. ALK2 functions as a BMP type I receptor and induces Indian hedgehog in chondrocytes during skeletal development. J Bone Miner Res 2003; 18: 1593-1604.
109. Yi SE, Daluiski A, Pederson R et al. The type I BMP receptor BMPRIB is required for chondrogenesis in the mouse limb. Development 2000; 127: 621-630.
110. Yoon BS, Pogue R, Ovchinnikov DA et al. BMPs regulate multiple aspects of growth-plate chondrogenesis through opposing actions on FGF pathways. Development 2006; 133: 4667-4678.
111. Afzal F, Pratap J, Ito K et al. Smad function and intranuclear targeting share a Runx2 motif required for osteogenic lineage induction and BMP2 responsive transcription. J Cell Physiol 2005; 204: 63-72.
112. Franceschi RT, Xiao G. Regulation of the osteoblast-specific transcription factor, Runx2: responsiveness to multiple signal transduction pathways. J Cell Biochem 2003; 88: 446-454.
113. Wang M, Jin H, Tang D et al. Smad1 plays an essential role in bone development and postnatal bone formation. Osteoarthritis Cartilage 2011; 19: 751-762.
114. Keller B, Yang T, Chen Y et al. Interaction of TGF and BMP signaling pathways during chondrogenesis. PLoS One 2011; 6: e16421.
115. Retting KN, Song B, Yoon BS et al. BMP canonical Smad signaling through Smad1 and Smad5 is required for endochondral bone formation. Development 2009; 136: 1093-1104.
116. Matsumoto Y, Otsuka F, Hino J et al. Bone morphogenetic protein-3b (BMP-3b) inhibits osteoblast differentiation via Smad2/3 pathway by counteracting Smad1/5/8 signaling. Mol Cell Endocrinol 2012; 350: 78-86.
117. Ishibashi N, Sasaki Y, Asakura Y. Myhre syndrome: a rare craniofacial disorder. Cranio 2014; 32: 300-306.
118. Le Goff C, Mahaut C, Abhyankar A et al. Mutations at a single codon in Mad homology 2 domain of SMAD4 cause Myhre syndrome. Nat Genet 2012; 44: 85-88.
119. Nojima J, Kanomata K, Takada Y et al. Dual roles of smad proteins in the conversion from myoblasts to osteoblastic cells by bone morphogenetic proteins. J Biol Chem 2010; 285: 15577-15586.
120. Zhang J, Tan X, Li W et al. Smad4 is required for the normal organization of the cartilage growth plate. Dev Biol 2005; 284: 311-322.
121. Tan X, Weng T, Zhang J et al. Smad4 is required for maintaining normal murine postnatal bone homeostasis. J Cell Sci 2007; 120: 2162-2170.
122. Salazar VS, Zarkadis N, Huang L et al. Embryonic ablation of osteoblast Smad4 interrupts matrix synthesis in response to canonical Wnt signaling and causes an osteogenesis-imperfecta-like phenotype. J Cell Sci 2013; 126 (Pt 21): 4974-4984.
123. Salazar VS, Zarkadis N, Huang L et al. Postnatal ablation of osteoblast Smad4 enhances proliferative responses to canonical Wnt signaling through interactions with catenin. J Cell Sci 2013; 126 (Pt 24): 5598-5609.
124. Billings PC, Fiori JL, Bentwood JL et al. Dysregulated BMP signaling and enhanced osteogenic differentiation of connective tissue progenitor cells from patients with fibrodysplasia ossificans progressiva (FOP). J Bone Miner Res 2008; 23: 305-313.
125. Gunnell LM, Jonason JH, Loiselle AE et al. TAK1 regulates cartilage and joint development via the MAPK and BMP signaling pathways. J Bone Miner Res 2010; 25: 1784-1797.
126. Gao L, Sheu TJ, Dong Y et al. TAK1 regulates SOX9 expression in chondrocytes and is essential for postnatal development of the growth plate and articular cartilages. J Cell Sci 2013; 126 (Pt 24): 5704-5713.
127. Greenblatt MB, Shim JH, Zou W et al. The p38 MAPK pathway is essential for skeletogenesis and bone homeostasis in mice. J Clin Invest 2010; 120: 2457-2473.
128. Ge C, Yang Q, Zhao G et al. Interactions between extracellular signalregulated kinase 1/2 and p38 MAP kinase pathways in the control of RUNX2 phosphorylation and transcriptional activity. J Bone Miner Res 2012; 27: 538-551.
129. Ulsamer A, Ortuño MJ, Ruiz S et al. BMP-2 induces Osterix expression through up-regulation of Dlx5 and its phosphorylation by p38. J Biol Chem 2008; 283: 3816-3826.
130. Ortuno MJ, Ruiz-Gaspa S, Rodriguez-Carballo E et al. p38 Regulates Expression of Osteoblast-specific Genes by Phosphorylation of Osterix. J Biol Chem 2010; 285: 31985-31994.
131. Celil AB, Hollinger JO, Campbell PG. Osx transcriptional regulation is mediated by additional pathways to BMP2/Smad signaling. J Cell Biochem 2005; 95: 518-528.
132. Choi YH, Gu YM, Oh JW et al. Osterix is regulated by Erk1/2 during osteoblast differentiation. Biochem Biophys Res Commun 2011; 415: 472-478.
133. Gazzerro E, Gangji V, Canalis E. Bone morphogenetic proteins induce the expression of noggin, which limits their activity in cultured rat osteoblasts. J Clin Invest 1998; 102: 2106-2114.
134. Abe E, Yamamoto M, Taguchi Y et al. Essential requirement of BMPs-2/4 for both osteoblast and osteoclast formation in murine bone marrow cultures from adult mice: antagonism by noggin. J Bone Miner Res 2000; 15: 663-673.
135. Wan DC, Pomerantz JH, Brunet LJ et al. Noggin suppression enhances in vitro osteogenesis and accelerates in vivo bone formation. J Biol Chem 2007; 282: 26450-26459.
136. Glaser DL, Economides AN, Wang L et al. In vivo somatic cell gene transfer of an engineered Noggin mutein prevents BMP4-induced heterotopic ossification. J Bone Joint Surg Am 2003; 85-A: 2332-2342.
137. Wang Y, Hong S, Li M et al. Noggin resistance contributes to the potent osteogenic capability of BMP9 in mesenchymal stem cells. J Orthop Res 2013; 31: 1796-1803.
138. Gong Y, Krakow D, Marcelino J et al. Heterozygous mutations in the gene encoding noggin affect human joint morphogenesis. Nat Genet 1999; 21: 302-304.
139. Wijgerde M, Karp S, McMahon J et al. Noggin antagonism of BMP4 signaling controls development of the axial skeleton in the mouse. Dev Biol 2005; 286: 149-157.
140. Stafford DA, Brunet LJ, Khokha MK et al. Cooperative activity of noggin and gremlin 1 in axial skeleton development. Development 2011; 138: 1005-1014.
141. Stafford DA, Monica SD, Harland RM. Follistatin interacts with Noggin in the development of the axial skeleton. Mech Dev 2014; 131: 78-85.
142. Devlin RD, Du Z, Pereira RC et al. Skeletal overexpression of noggin results in osteopenia and reduced bone formation. Endocrinology 2003; 144: 1972-1978.
143. Wu XB, Li Y, Schneider A et al. Impaired osteoblastic differentiation, reduced bone formation, and severe osteoporosis in nogginoverexpressing mice. J Clin Invest 2003; 112: 924-934.
144. Pathi S, Rutenberg JB, Johnson RL et al. Interaction of IHH and BMP/ Noggin signaling during cartilage differentiation. Dev Biol 1999; 209: 239-253.
145. Warren SM, Brunet LJ, Harland RM et al. The BMP antagonist noggin regulates cranial suture fusion. Nature 2003; 422: 625-629.
146. Zehentner BK, Haussmann A, Burtscher H. The bone morphogenetic protein antagonist Noggin is regulated by Sox9 during endochondral differentiation. Dev Growth Differ 2002; 44: 1-9.
147. Kalajzic I, Kalajzic Z, Hurley MM et al. Stage specific inhibition of osteoblast lineage differentiation by FGF2 and noggin. J Cell Biochem 2003; 88: 1168-1176.
148. Reinhold MI, Abe M, Kapadia RM et al. FGF18 represses noggin expression and is induced by calcineurin. J Biol Chem 2004; 279: 38209-38219.
149. Nakayama N, Han CE, Scully S et al. A novel chordin-like protein inhibitor for bone morphogenetic proteins expressed preferentially in mesenchymal cell lineages. Dev Biol 2001; 232: 372-387.
150. Fisher S, Halpern ME. Patterning the zebrafish axial skeleton requires early chordin function. Nat Genet 1999; 23: 442-446.
151. Oren A, Toporik A, Biton S et al. hCHL2, a novel chordin-related gene, displays differential expression and complex alternative splicing in human tissues and during myoblast and osteoblast maturation. Gene 2004; 331: 17-31.
152. Nakayama N, Han CY, Cam L et al. A novel chordin-like BMP inhibitor, CHL2, expressed preferentially in chondrocytes of developing cartilage and osteoarthritic joint cartilage. Development 2004; 131: 229-240.
153. Petryk A, Shimmi O, Jia XH et al. Twisted gastrulation and chordin inhibit differentiation and mineralization in MC3T3-E1 osteoblastlike cells. Bone 2005; 36: 617-626.
154. Zhang D, Ferguson CM, O'Keefe RJ et al. A role for the BMP antagonist chordin in endochondral ossification. J BoneMiner Res 2002; 17: 293-300.
155. Anderson RM, Lawrence AR, Stottmann RW et al. Chordin and noggin promote organizing centers of forebrain development in the mouse. Development 2002; 129: 4975-4987.
156. Yan X, Liu Z, Chen Y. Regulation of TGF-beta signaling by Smad7. Acta Biochim Biophys Sin (Shanghai) 2009; 41: 263-272.
157. Moustakas A, Heldin CH. The regulation of TGF signal transduction. Development 2009; 136: 3699-3714.
158. Scharstuhl A, Diepens R, Lensen J et al. Adenoviral overexpression of Smad-7 and Smad-6 differentially regulates TGF-beta-mediated chondrocyte proliferation and proteoglycan synthesis. Osteoarthritis Cartilage 2003; 11: 773-782.
159. Valcourt U, Gouttenoire J, Moustakas A et al. Functions of transforming growth factor-beta family type I receptors and Smad proteins in the hypertrophic maturation and osteoblastic differentiation of chondrocytes. J Biol Chem 2002; 277: 33545-33558.
160. Li X, Ionescu AM, Schwarz EM et al. Smad6 is induced by BMP-2 and modulates chondrocyte differentiation. J Orthop Res 2003; 21: 908-913.
161. Yano M, Inoue Y, Tobimatsu T et al. Smad7 inhibits differentiation and mineralization of mouse osteoblastic cells. Endocr J 2012; 59: 653-662.
162. Horiki M, Imamura T, Okamoto M et al. Smad6/Smurf1 overexpression in cartilage delays chondrocyte hypertrophy and causes dwarfism with osteopenia. J Cell Biol 2004; 165: 433-445.
163. Shen R, Chen M, Wang YJ et al. Smad6 interacts with Runx2 and mediates Smad ubiquitin regulatory factor 1-induced Runx2 degradation. J Biol Chem 2006; 281: 3569-3576.
164. Wang Q, Wei X, Zhu T et al. Bone morphogenetic protein 2 activates Smad6 gene transcription through bone-specific transcription factor Runx2. J Biol Chem 2007; 282: 10742-10748.
165. Iwai T, Murai J, Yoshikawa H et al. Smad7 Inhibits chondrocyte differentiation at multiple steps during endochondral bone formation and down-regulates p38 MAPK pathways. J Biol Chem 2008; 283: 27154-27164.
166. Wu Q, Wang M, Zuscik MJ et al. Regulation of embryonic endochondral ossification by Smurf2. J Orthop Res 2008; 26: 704-712.
167. Yamashita M, Ying SX, Zhang GM et al. Ubiquitin ligase Smurf1 controls osteoblast activity and bone homeostasis by targeting MEKK2 for degradation. Cell 2005; 121: 101-113.
168. Qi H, Jin M, Duan Y et al. FGFR3 induces degradation of BMP type I receptor to regulate skeletal development. Biochim Biophys Acta 2014; 1843: 1237-1247.
169. Tsubakihara Y, Hikita A, Yamamoto S et al. Arkadia enhances BMP signalling through ubiquitylation and degradation of Smad6. J Biochem 2015; 158: 61-71.
170. Shimada K, Suzuki N, Ono Y et al. Ubc9 promotes the stability of Smad4 and the nuclear accumulation of Smad1 in osteoblast-like Saos-2 cells. Bone 2008; 42: 886-893.
171. Yukita A, Hosoya A, Ito Y et al. Ubc9 negatively regulates BMPmediated osteoblastic differentiation in cultured cells. Bone 2012; 50: 1092-1099.
172. Herhaus L, Al-Salihi MA, Dingwell KS et al. USP15 targets ALK3/ BMPR1A for deubiquitylation to enhance bone morphogenetic protein signalling. Open Biol 2014; 4: 140065.
173. Kawamura I, Maeda S, Imamura K et al. SnoN suppresses maturation of chondrocytes by mediating signal cross-talk between transforming growth factor and bone morphogenetic protein pathways. J Biol Chem 2012; 287: 29101-29113.
174. Usui M, Yoshida Y, Tsuji K et al. Tob deficiency superenhances osteoblastic activity after ovariectomy to block estrogen deficiency-induced osteoporosis. Proc Natl Acad Sci USA 2004; 101: 6653-6658.
175. Yoshida Y, Tanaka S, Umemori H et al. Negative regulation of BMP/ Smad signaling by Tob in osteoblasts. Cell 2000; 103: 1085-1097.
176. Li Z, Hassan MQ, Volinia S et al. A microRNA signature for a BMP2-induced osteoblast lineage commitment program. Proc Natl Acad Sci USA 2008; 105: 13906-13911.
177. Balderman JAF, Lee HY, Mahoney CE et al. Bone morphogenetic protein-2 decreases microRNA-30b and microRNA-30c to promote vascular smooth muscle cell calcification. J Am Heart Assoc 2012; 1: e003905-e003905.
178. Wu T, Zhou H, Hong Y et al. miR-30 family members negatively regulate osteoblast differentiation. J Biol Chem 2012; 287: 7503-7511.
179. Gámez B, Rodríguez-Carballo E, Bartrons R et al. MicroRNA-322 (miR-322) and its target protein Tob2 modulate Osterix (Osx) mRNA stability. J Biol Chem 2013; 288: 14264-14275.
180. Itoh T, Nozawa Y, Akao Y. MicroRNA-141 and-200a are involved in bone morphogenetic protein-2-induced mouse pre-osteoblast differentiation by targeting distal-less homeobox 5. J Biol Chem 2009; 284: 19272-19279.
181. Kureel J, Dixit M, Tyagi AM et al. miR-542-3p suppresses osteoblast cell proliferation and differentiation, targets BMP-7 signaling and inhibits bone formation. Cell Death Dis 2014; 5: e1050.
182. Zhang JF, Fu WM, He ML et al. MiRNA-20a promotes osteogenic differentiation of human mesenchymal stem cells by co-regulating BMP signaling. RNA Biol 2011; 8: 829-838.
183. Nakamura Y, Inloes JB, Katagiri T et al. Chondrocyte-specific microRNA-140 regulates endochondral bone development and targets Dnpep to modulate bone morphogenetic protein signaling. Mol Cell Biol 2011; 31: 3019-3028.
184. Borgonio Cuadra VM, González-Huerta NC, Romero-Córdoba S et al. Altered expression of circulating microRNA in plasma of patients with primary osteoarthritis and in silico analysis of their pathways. PLoS One 2014; 9: e97690.
185. Díaz-Prado S, Cicione C, Muiños-López E et al. Characterization of microRNA expression profiles in normal and osteoarthritic human chondrocytes. BMC Musculoskelet Disord 2012; 13: 144.
186. Tew SR, Vasieva O, Peffers MJ et al. Post-transcriptional gene regulation following exposure of osteoarthritic human articular chondrocytes to hyperosmotic conditions. Osteoarthritis Cartilage 2011; 19: 1036-1046.
187. Jin L, Zhao J, Jing W et al. Role of miR-146a in human chondrocyte apoptosis in response to mechanical pressure injury in vitro. Int J Mol Med 2014; 34: 451-463.
188. Li J, Huang J, Dai L et al. miR-146a, an IL-1 responsive miRNA, induces vascular endothelial growth factor and chondrocyte apoptosis by targeting Smad4. Arthritis Res Ther 2012; 14: R75.
189. Lin EA, Kong L, Bai XH et al. miR-199a, a bone morphogenic protein 2-responsive microRNA, regulates chondrogenesis via direct targeting to Smad1. J Biol Chem 2009; 284: 11326-11335.
190. Furumatsu T, Asahara H. Histone acetylation influences the activity of Sox9-related transcriptional complex. Acta Med Okayama 2010; 64: 351-357.
191. Lee HL, Yu B, Deng P et al. Transforming growth factor-induced KDM4B promotes chondrogenic differentiation of human mesenchymal. Stem Cells 2016; 34: 711-719.
192. Lee ZH, Kim HJ, Ryoo HM. A novel osteogenic activity of suberoylanilide hydroxamic acid is synergized by BMP-2. J Bone Metab 2015; 22: 51-56.
193. Cho YD, Yoon WJ, Kim WJ et al. Epigenetic modifications and canonical wingless/int-1 class (WNT) signaling enable trans-differentiation of nonosteogenic cells into osteoblasts. J Biol Chem 2014; 289: 20120-20128.
194. Zhou S, Eid K, Glowacki J. Cooperation between TGF and Wnt pathways during chondrocyte and adipocyte differentiation of human marrow stromal cells. J Bone Miner Res 2003; 19: 463-470.
195. Dao DY, Yang X, Chen D et al. Axin1 and Axin2 are regulated by TGFand mediate cross-talk between TGF-and Wnt signaling pathways. Ann NY Acad Sci 2007; 1116: 82-99.
196. McCarthy TL, Centrella M. Novel links among Wnt and TGF-beta signaling and Runx2. Mol Endocrinol 2010; 24: 587-597.
197. Liu Z, Tang Y, Qiu T et al. A dishevelled-1/Smad1 interaction couples WNT and bone morphogenetic protein signaling pathways in uncommitted bone marrow stromal cells. J Biol Chem 2006; 281: 17156-17163.
198. Rawadi G, Vayssière B, Dunn F et al. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res 2003; 18: 1842-1853.
199. Zhang M, Yan Y, Lim YB et al. BMP-2 modulates beta-catenin signaling through stimulation of Lrp5 expression and inhibition of beta-TrCP expression in osteoblasts. J Cell Biochem 2009; 108: 896-905.
200. Papathanasiou I, Malizos KN, Tsezou A. Bone morphogenetic protein-2-induced Wnt/-catenin signaling pathway activation through enhanced low-density-lipoprotein receptor-related protein 5 catabolic activity contributes to hypertrophy in osteoarthritic chondrocytes. Arthritis Res Ther 2012; 14: R82.
201. Tang N, Song WX, Luo J et al. BMP-9-induced osteogenic differentiation of mesenchymal progenitors requires functional canonical Wnt/betacatenin signalling. J Cell Mol Med 2009; 13: 2448-2464.
202. Rodríguez-Carballo E, Ulsamer A, Susperregui AR et al. Conserved regulatory motifs in osteogenic gene promoters integrate cooperative effects of canonical Wnt and BMP pathways. J Bone Miner Res 2011; 26: 718-729.
203. Zhang R, Oyajobi BO, Harris SE et al. Wnt/-catenin signaling activates bone morphogenetic protein 2 expression in osteoblasts. Bone 2013; 52: 145-156.
204. Jiang T, Ge S, Shim YH et al. Bone morphogenetic protein is required for fibroblast growth factor 2-dependent later-stage osteoblastic differentiation in cranial suture cells. Int J Clin Exp Pathol 2015; 8: 2946-2954.
205. Naganawa T, Xiao L, Coffin JD et al. Reduced expression and function of bone morphogenetic protein-2 in bones of Fgf2 null mice. J Cell Biochem 2008; 103: 1975-1988.
206. Agas D, Sabbieti MG, Marchetti L et al. FGF-2 enhances Runx-2/Smads nuclear localization in BMP-2 canonical signaling in osteoblasts. J Cell Physiol 2013; 228: 2149-2158.
207. Nagayama T, Okuhara S, Ota MS et al. FGF18 accelerates osteoblast differentiation by upregulating Bmp2 expression. Congenit Anom (Kyoto) 2013; 53: 83-88.
208. Fakhry A, Ratisoontorn C, Vedhachalam C et al. Effects of FGF-2/-9 in calvarial bone cell cultures: differentiation stage-dependent mitogenic effect, inverse regulation of BMP-2 and noggin, and enhancement of osteogenic potential. Bone 2005; 36: 254-266.
209. Hughes-Fulford M, Li CF. The role of FGF-2 and BMP-2 in regulation of gene induction, cell proliferation and mineralization. J Orthop Surg Res 2011; 6: 8.
210. Park JB. Effects of the combination of fibroblast growth factor-2 and bone morphogenetic protein-2 on the proliferation and differentiation of osteoprecursor cells. Adv Clin Exp Med 2014; 23: 463-467.
211. Matsushita T, Wilcox WR, Chan YY et al. FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway. Hum Mol Genet 2009; 18: 227-240.
212. Allen JM, McGlinn E, Hill A et al. Autopodial development is selectively impaired by misexpression of chordin-like 1 in the chick limb. Dev Biol 2013; 381: 159-169.
213. Long F, Chung UI, Ohba S et al. IHH signaling is directly required for the osteoblast lineage in the endochondral skeleton. Development 2004; 131: 1309-1318.
214. Lenton K, James AW, Manu A et al. Indian hedgehog positively regulates calvarial ossification and modulates bone morphogenetic protein signaling. Genesis 2011; 49: 784-796.
215. Hojo H, Ohba S, Taniguchi K et al. Hedgehog-Gli activators direct osteo-chondrogenic function of bone morphogenetic protein toward osteogenesis in the perichondrium. J Biol Chem 2013; 288: 9924-9932.
216. Zhao M, Ko SY, Liu JH et al. Inhibition of microtubule assembly in osteoblasts stimulates bone morphogenetic protein 2 expression and bone formation through transcription factor Gli2. Mol Cell Biol 2008; 29: 1291-1305.
217. Zhao M, Qiao M, Harris SE et al. The zinc finger transcription factor Gli2 mediates bone morphogenetic protein 2 expression in osteoblasts in response to hedgehog signaling. Mol Cell Biol 2006; 26: 6197-6208.
218. Minina E, Wenzel HM, Kreschel C et al. BMP and IHH/PTHrP signaling interact to coordinate chondrocyte proliferation and differentiation. Development 2001; 128: 4523-4534.
219. Kameda T, Koike C, Saitoh K et al. Developmental patterning in chondrocytic cultures by morphogenic gradients: BMP induces expression of indian hedgehog and noggin. Genes Cells 1999; 4: 175-184.
220. Grimsrud CD, Romano PR, D'Souza M et al. BMP-6 is an autocrine stimulator of chondrocyte differentiation. J Bone Miner Res 1999; 14: 475-482.
221. Mak KK, Kronenberg HM, Chuang PT et al. Indian hedgehog signals independently of PTHrP to promote chondrocyte hypertrophy. Development 2008; 135: 1947-1956.
222. Mak KK, Chen MH, Day TF et al. Wnt/beta-catenin signaling interacts differentially with IHH signaling in controlling endochondral bone and synovial joint formation. Development 2006; 133: 3695-3707.
223. Zeng L. SHH establishes an Nkx3. 2/Sox9 autoregulatory loop that is maintained by BMP signals to induce somitic chondrogenesis. Genes Dev 2002; 16: 1990-2005.
224. Choi KY, Kim HJ, Lee MH et al. Runx2 regulates FGF2-induced Bmp2 expression during cranial bone development. Dev Dyn 2005; 233: 115-121.
225. Tezuka K, Yasuda M, Watanabe N et al. Stimulation of osteoblastic cell differentiation by Notch. J Bone Miner Res 2002; 17: 231-239.
226. Nobta M, Tsukazaki T, Shibata Y et al. Critical regulation of bone morphogenetic protein-induced osteoblastic differentiation by Delta1/Jagged1-activated Notch1 signaling. J Biol Chem 2005; 280: 15842-15848.
227. de Jong DS, Steegenga WT, Hendriks JM et al. Regulation of Notch signaling genes during BMP2-induced differentiation of osteoblast precursor cells. Biochem Biophys Res Commun 2004; 320: 100-107.
228. Atfi A, Baron R. PTH battles TGF in bone. Nat Cell Biol 2010; 12: 205-207.
229. Yu B, Zhao X, Yang C et al. Parathyroid hormone induces differentiation of mesenchymal stromal/stem cells by enhancing bone morphogenetic protein signaling. J Bone Miner Res 2012; 27: 2001-2014.
230. Kobayashi T, Soegiarto DW, Yang Y et al. Indian hedgehog stimulates periarticular chondrocyte differentiation to regulate growth plate length independently of PTHrP. J Clin Invest 2005; 115: 1734-1742.
231. Bocciardi R, Bordo D, Di Duca M et al. Mutational analysis of the ACVR1 gene in Italian patients affected with fibrodysplasia ossificans progressiva: confirmations and advancements. Eur J Hum Genet 2009; 17: 311-318.
232. Gregson CL, Hollingworth P, Williams M et al. A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date. Bone 2011; 48: 654-658.
233. Petrie KA, Lee WH, Bullock AN et al. Novel mutations in ACVR1 result in atypical features in two fibrodysplasia ossificans progressiva patients. PLoS One 2009; 4: e5005.
234. Su P, Ding H, Huang D et al. A 4. 6 kb genomic duplication on 20p12. 2-12. 3 is associated with brachydactyly type A2 in a Chinese family. J Med Genet 2011; 48: 312-316.
235. Lehmann K, Seemann P, Boergermann J et al. A novel R486Q mutation in BMPR1B resulting in either a brachydactyly type C/symphalangism-like phenotype or brachydactyly type A2. Eur J Hum Genet 2006; 14: 1248-1254.
236. Lehmann K, Seemann P, Stricker S et al. Mutations in bone morphogenetic protein receptor 1B cause brachydactyly type A2. Proc Natl Acad Sci USA 2003; 100: 12277-12282.
237. Plöger F, Seemann P, Schmidt-von Kegler M et al. Brachydactyly type A2 associated with a defect in proGDF5 processing. Hum Mol Genet 2008; 17: 1222-1233.
238. Seemann P, Schwappacher R, Kjaer KW et al. Activating and deactivating mutations in the receptor interaction site of GDF5 cause symphalangism or brachydactyly type A2. J Clin Invest 2005; 115: 2373-2381.
239. Dathe K, Kjaer KW, Brehm A et al. Duplications involving a conserved regulatory element downstream of BMP2 are associated with brachydactyly type A2. Am J Hum Genet 2009; 84: 483-492.
240. Thomas JT, Kilpatrick MW, Lin K et al. Disruption of human limb morphogenesis by a dominant negative mutation in CDMP1. Nat Genet 1997; 17: 58-64.
241. Lindor NM, Gunawardena SR, Thibodeau SN. Mutations of SMAD4 account for both LAPS and Myhre syndromes. Am J Med Genet 2012; 158A: 1520-1521.
242. Lehmann K, Seemann P, Silan F et al. A new subtype of brachydactyly type B caused by point mutations in the bone morphogenetic protein antagonist NOGGIN. Am J Hum Genet 2007; 81: 388-396.
243. Dixon ME, Armstrong P, Stevens DB et al. Identical mutations in NOG can cause either tarsal/carpal coalition syndrome or proximal symphalangism. Genet Med 2001; 3: 349-353.
244. Hirshoren N, Gross M, Banin E et al. P35S mutation in the NOG gene associated with Teunissen-Cremers syndrome and features of multiple NOG joint-fusion syndromes. Eur J Med Genet 2008; 51: 351-357.
245. Campos-Xavier B, Saraiva JM, Savarirayan R et al. Phenotypic variability at the TGF-beta1 locus in Camurati-Engelmann disease. Hum Genet 2001; 109: 653-658.
246. Kinoshita A, Saito T, Tomita H et al. Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease. Nat Genet 2000; 26: 19-20.
247. Sakuma M, Hatsushika K, Koyama K et al. TGF-type I receptor kinase inhibitor down-regulates rheumatoid synoviocytes and prevents the arthritis induced by type II collagen antibody. Int Immunol 2006; 19: 117-126.
248. Yu PB, Deng DY, Lai CS et al. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med 2008; 14: 1363-1369.
249. Lories RJ, Luyten FP. Bone morphogenetic protein signaling in joint homeostasis and disease. Cytokine Growth Factor Rev 2005; 16: 287-298.
250. Zouani OF, Chollet C, Guillotin B et al. Differentiation of pre-osteoblast cells on poly(ethylene terephthalate) grafted with RGD and/or BMPs mimetic peptides. Biomaterials 2010; 31: 8245-8253.
251. Dünker N, Krieglstein K. Tgfbeta2-/-Tgfbeta3-/-double knockout mice display severe midline fusion defects and early embryonic lethality. Anat Embryol 2002; 206: 73-83.
252. Gu Z, Reynolds EM, Song J et al. The type I serine/threonine kinase receptor ActRIA (ALK2) is required for gastrulation of the mouse embryo. Development 1999; 126: 2551-2561.
253. Nomura M, Li E. Smad2 role in mesoderm formation, left-right patterning and craniofacial development. Nature 1998; 393: 786-790.
254. Zhou S. TGF regulates-catenin signaling and osteoblast differentiation in human mesenchymal stem cells. J Cell Biochem 2011; 112: 1651-1660.
255. Tachi K, Takami M, Sato H et al. Enhancement of bone morphogenetic protein-2-induced ectopic bone formation by transforming growth factor 1. Tissue Eng Part A 2011; 17: 597-606.
256. Sasaki T, Ito Y, Bringas P Jr et al. TGFbeta-mediated FGF signaling is crucial for regulating cranial neural crest cell proliferation during frontal bone development. Development 2006; 133: 371-381.
257. van der Horst G, Farih-Sips H, Löwik CW et al. Hedgehog stimulates only osteoblastic differentiation of undifferentiated KS483 cells. Bone 2003; 33: 899-910.
258. Zhang R, Edwards JR, Ko SY et al. Transcriptional regulation of BMP2 expression by the PTH-CREB signaling pathway in osteoblasts. PLoS One 2011; 6: e20780.